Evidence map›Paper›PMID 39216327›Full record

ArticleBiomaterials2025

Intravascular delivery of an MK2 inhibitory peptide to prevent restenosis after angioplasty.

J William Tierney, R Paolo Francisco, Fang Yu, Jinqi Ma, Joyce Cheung-Flynn, Megan C Keech, Richard D'Arcy, Veeraj M Shah, Anna R Kittel, Devin J Chang and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

J William TierneyDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
R Paolo FranciscoDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
Fang YuDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
Jinqi MaDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
Joyce Cheung-FlynnDivision of Vascular Surgery, Department of Surgery, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Megan C KeechDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
Richard D'ArcyDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37235, USA; Chemical Engineering, School of Engineering of Matter, Transport and Energy, Arizona State University, Tempe, AZ, USA.
Veeraj M ShahDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
Anna R KittelDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
Devin J ChangDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
Joshua T McCuneDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
Mariah G BezoldDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
Adrian N AligwekweMedical Scientist Training Program, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA; North Carolina State University, Raleigh, NC, 27695, USA.
Rebecca S CookDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37235, USA; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Joshua A BeckmanDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Colleen M BrophyDivision of Vascular Surgery, Department of Surgery, Vanderbilt University Medical Center, Nashville, TN, 37232, USA; Veterans Affairs Medical Center, VA Tennessee Valley Healthcare System, Nashville, TN, 37212, USA.
Craig L DuvallDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37235, USA. Electronic address: craig.duvall@vanderbilt.edu.

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8M
Integrated Training in Engineering and DiabetesT32DK101003 · NIDDK · VANDERBILT UNIVERSITY · PI Jamey D. Young · 2014 to 2026
$3.9M
MK2 Inhibitory Nanoplexes to Enhance Long-Term Vascular Graft PatencyR01HL122347 · NHLBI · VANDERBILT UNIVERSITY · PI DUVALL, CRAIG LEWIS · 2016 to 2020
$2.2M
In vivo vascular delivery of an MK2 inhibitory peptide for the prevention of smooth muscle cell phenotype switch and intimal hyperplasia.F31HL162476 · NHLBI · VANDERBILT UNIVERSITY · PI TIERNEY, JOHN W · 2022 to 2023
$70k
NCI NIH HHS P30 CA068485NHLBI NIH HHS F31 HL162476NHLBI NIH HHS R01 HL122347NIDDK NIH HHS T32 DK101003
6 · The paper itself

Abstract

Peripheral artery disease is commonly treated with balloon angioplasty, a procedure involving minimally invasive, transluminal insertion of a catheter to the site of stenosis, where a balloon is inflated to open the blockage, restoring blood flow. However, peripheral angioplasty has a high rate of restenosis, limiting long-term patency. Therefore, angioplasty is sometimes paired with delivery of cytotoxic drugs like paclitaxel to reduce neointimal tissue formation. We pursue intravascular drug delivery strategies that target the underlying cause of restenosis - intimal hyperplasia resulting from stress-induced vascular smooth muscle cell switching from the healthy contractile into a pathological synthetic phenotype. We have established MAPKAP kinase 2 (MK2) as a driver of this phenotype switch and seek to establish convective and contact transfer (coated balloon) methods for MK2 inhibitory peptide delivery to sites of angioplasty. Using a flow loop bioreactor, we showed MK2 inhibition in ex vivo arteries suppresses smooth muscle cell phenotype switching while preserving vessel contractility. A rat carotid artery balloon injury model demonstrated inhibition of intimal hyperplasia following MK2i coated balloon treatment in vivo. These studies establish both convective and drug coated balloon strategies as promising approaches for intravascular delivery of MK2 inhibitory formulations to improve efficacy of balloon angioplasty.

Indexed as

Intracellular Signaling Peptides and ProteinsProtein Serine-Threonine KinasesRats, Sprague-DawleyAngioplastyAngioplasty, BalloonAnimalsDrug Delivery SystemsHyperplasiaMaleMAP-Kinase-Activated Kinase 2Muscle, Smooth, VascularMyocytes, Smooth MuscleNeointimaPeptidesRatsIntracellular Signaling Peptides and ProteinsMAP-Kinase-Activated Kinase 2PeptidesProtein Serine-Threonine KinasesDrug coated balloonsDrug deliveryIntravascular deliveryPeripheral artery diseaseRestenosis

Identifiers

PMID39216327
PMCPMC12023847

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.